IPO registrations (S-1, F-1) · Registrants
Rosetta Genomics Ltd.
- SEC CIK
- 1362959 · filings on EDGAR ↗
- Registration
- Form F-1, first filed 2006-09-01, last 2017-10-16; 5 initial registrations, 11 amendments
- Outcome
- Final prospectus filed 2007-02-27; declared effective 2007-02-26
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- L3
- Business address
- 10 PLAUT STREET, SCIENCE PARK, POB 4059, Rehovot, L3 76706
- EDGAR entity type
- other
- Insiders and CEO pay
- Rosetta Genomics Ltd. on the corporate pages
Offering terms
- Proposed price range
- $7.50–$8.50 per share (F-1/A filed 2007-02-14)
- Final price
- $7.00 per share, below the range (424B4 filed 2007-02-27, an initial public offering)
- Shares sold
- 3,750,000
- Gross proceeds
- $26,250,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ROSG
- Lead underwriters
- Oppenheimer
- Syndicate
- C.e. Unterberg, Towbin
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: Rosetta Genomics Ltd. EXACT (CIK (EXACT))
- SEC filer: Rosetta Genomics Ltd. EXACT (CIK (EXACT))
Filings 35
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2006-09-01 | F-1 | F-1 (foreign registration) | Rosetta Genomics Ltd. | 0001144204-06-036878 ↗ |
| 2006-09-21 | F-1/A | F-1/A (amendment) | Rosetta Genomics Ltd. | 0001144204-06-039351 ↗ |
| 2007-01-23 | F-1/A | F-1/A (amendment) | Rosetta Genomics Ltd. | 0001144204-07-002889 ↗ |
| 2007-02-14 | F-1/A | F-1/A (amendment) | Rosetta Genomics Ltd. | 0001144204-07-007401 ↗ |
| 2007-02-26 | EFFECT | EFFECT (declared effective) | Rosetta Genomics Ltd. | 9999999995-07-000761 ↗ |
| 2007-02-27 | 424B4 | 424B4 (final prospectus) | Rosetta Genomics Ltd. | 0001144204-07-010127 ↗ |
| 2008-08-28 | EFFECT | EFFECT (declared effective) | Rosetta Genomics Ltd. | 9999999995-08-002775 ↗ |
| 2009-06-22 | EFFECT | EFFECT (declared effective) | Rosetta Genomics Ltd. | 9999999995-09-001726 ↗ |
| 2009-09-23 | EFFECT | EFFECT (declared effective) | Rosetta Genomics Ltd. | 9999999995-09-002648 ↗ |
| 2009-11-24 | EFFECT | EFFECT (declared effective) | Rosetta Genomics Ltd. | 9999999995-09-003292 ↗ |
| 2010-12-22 | EFFECT | EFFECT (declared effective) | Rosetta Genomics Ltd. | 9999999995-10-003685 ↗ |
| 2011-03-22 | EFFECT | EFFECT (declared effective) | Rosetta Genomics Ltd. | 9999999995-11-000738 ↗ |
| 2011-11-10 | EFFECT | EFFECT (declared effective) | Rosetta Genomics Ltd. | 9999999995-11-003270 ↗ |
| 2012-06-25 | F-1 | F-1 (foreign registration) | Rosetta Genomics Ltd. | 0001144204-12-036316 ↗ |
| 2012-07-26 | F-1/A | F-1/A (amendment) | Rosetta Genomics Ltd. | 0001144204-12-041182 ↗ |
| 2012-08-02 | F-1/A | F-1/A (amendment) | Rosetta Genomics Ltd. | 0001144204-12-042550 ↗ |
| 2012-08-02 | EFFECT | EFFECT (declared effective) | Rosetta Genomics Ltd. | 9999999995-12-002360 ↗ |
| 2012-08-03 | 424B4 | 424B4 (final prospectus) | Rosetta Genomics Ltd. | 0001144204-12-042834 ↗ |
| 2012-12-19 | EFFECT | EFFECT (declared effective) | Rosetta Genomics Ltd. | 9999999995-12-003580 ↗ |
| 2015-11-10 | EFFECT | EFFECT (declared effective) | Rosetta Genomics Ltd. | 9999999995-15-003019 ↗ |
| 2016-03-30 | EFFECT | EFFECT (declared effective) | Rosetta Genomics Ltd. | 9999999995-16-004086 ↗ |
| 2016-12-08 | F-1 | F-1 (foreign registration) | Rosetta Genomics Ltd. | 0001144204-16-138566 ↗ |
| 2017-02-14 | F-1/A | F-1/A (amendment) | Rosetta Genomics Ltd. | 0001144204-17-008867 ↗ |
| 2017-02-16 | EFFECT | EFFECT (declared effective) | Rosetta Genomics Ltd. | 9999999995-17-000396 ↗ |
| 2017-05-01 | EFFECT | EFFECT (declared effective) | Rosetta Genomics Ltd. | 9999999995-17-001118 ↗ |
| 2017-05-08 | F-1 | F-1 (foreign registration) | Rosetta Genomics Ltd. | 0001144204-17-025204 ↗ |
| 2017-05-15 | F-1/A | F-1/A (amendment) | Rosetta Genomics Ltd. | 0001144204-17-027089 ↗ |
| 2017-05-17 | F-1/A | F-1/A (amendment) | Rosetta Genomics Ltd. | 0001144204-17-028205 ↗ |
| 2017-07-26 | F-1/A | F-1/A (amendment) | Rosetta Genomics Ltd. | 0001144204-17-038186 ↗ |
| 2017-07-28 | F-1/A | F-1/A (amendment) | Rosetta Genomics Ltd. | 0001144204-17-038952 ↗ |
| 2017-08-02 | F-1/A | F-1/A (amendment) | Rosetta Genomics Ltd. | 0001144204-17-039916 ↗ |
| 2017-08-03 | EFFECT | EFFECT (declared effective) | Rosetta Genomics Ltd. | 9999999995-17-002030 ↗ |
| 2017-08-07 | 424B4 | 424B4 (final prospectus) | Rosetta Genomics Ltd. | 0001144204-17-040698 ↗ |
| 2017-10-16 | F-1 | F-1 (foreign registration) | Rosetta Genomics Ltd. | 0001144204-17-052664 ↗ |
| 2017-10-27 | EFFECT | EFFECT (declared effective) | Rosetta Genomics Ltd. | 9999999995-17-002807 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2007-02-14 | F-1/A | registration statement | $7.50–$8.50 | 3,750,000 | - | Nasdaq ROSG | 2 | primary document; range, price line, shares headline, proceeds computed, price outside the range dropped, cover names 2 | document ↗ | |
| 2007-02-27 | 424B4 | final prospectus | $7.00 | 3,750,000 | $26,250,000 | Nasdaq ROSG | 2 | primary document; price sentence, shares headline, proceeds table, cover names 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Sabby Healthcare Master Fund, Ltd. | TenPercentOwner | 5 | 2018 | ||
| SABBY MANAGEMENT, LLC | TenPercentOwner | 6 | 2018–2019 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2012-02-09 | Rosetta Genomics Ltd. | Biotechnology | $1,750,000 | $1,750,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Rosetta Genomics Ltd. | Form D private offerings | CIK (EXACT) | |
| SEC filer | Rosetta Genomics Ltd. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, L3 first:
- CANNAPOWDER, INC. L3
- BIOCANCELL THERAPEUTICS INC. L3
- Can-Fite BioPharma Ltd. L3
- RedHill Biopharma Ltd. L3
- KAMADA LTD L3
- MAPI - PHARMA LTD L3
- NeuroDerm Ltd. L3
- Advanced Inhalation Therapies (AIT) Ltd. L3
- Silenseed Ltd. L3
- SciSparc Ltd. L3
In other datasets, the same topic (Health) in L3:
- Form D issuer: Agada Medical Ltd. (Form D private offerings)
Interests: Pharmaceutical Preparations · Health